Lead Program (Unnamed)
Cannabis Use Disorder (CUD) / Cannabis Withdrawal Syndrome (CWS)
Phase 2Active
Key Facts
Indication
Cannabis Use Disorder (CUD) / Cannabis Withdrawal Syndrome (CWS)
Phase
Phase 2
Status
Active
Company
About PleoPharma
PleoPharma is a clinical-stage biotech company developing novel treatments for CNS and substance abuse disorders, with a primary focus on Cannabis Use Disorder (CUD). Founded by physicians who identified a significant unmet need in cannabis withdrawal, the company's lead asset has progressed through Phase 2 trials. With a seasoned leadership team and board, PleoPharma is positioned to advance its pipeline in a growing market that currently lacks FDA-approved pharmacological treatments.
View full company profile